- Home
- JLL vs UTHR Comparison
JLL vs UTHR Comparison
Compare JLL & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JLL
- UTHR
- Stock Information
- Founded
- JLL 1997
- UTHR 1996
- Country
- JLL United States
- UTHR United States
- Employees
- JLL N/A
- UTHR N/A
- Industry
- JLL Real Estate
- UTHR Biotechnology: Pharmaceutical Preparations
- Sector
- JLL Finance
- UTHR Health Care
- Exchange
- JLL Nasdaq
- UTHR Nasdaq
- Market Cap
- JLL 12.1B
- UTHR 14.4B
- IPO Year
- JLL 1997
- UTHR 1999
- Fundamental
- Price
- JLL $257.05
- UTHR $297.02
- Analyst Decision
- JLL Strong Buy
- UTHR Buy
- Analyst Count
- JLL 7
- UTHR 13
- Target Price
- JLL $310.00
- UTHR $383.08
- AVG Volume (30 Days)
- JLL 504.0K
- UTHR 551.5K
- Earning Date
- JLL 08-06-2025
- UTHR 07-30-2025
- Dividend Yield
- JLL N/A
- UTHR N/A
- EPS Growth
- JLL 78.40
- UTHR 18.86
- EPS
- JLL 11.07
- UTHR 25.10
- Revenue
- JLL $24,054,800,000.00
- UTHR $2,994,100,000.00
- Revenue This Year
- JLL $10.02
- UTHR $14.30
- Revenue Next Year
- JLL $8.25
- UTHR $6.32
- P/E Ratio
- JLL $23.22
- UTHR $11.79
- Revenue Growth
- JLL 13.63
- UTHR 19.84
- 52 Week Low
- JLL $194.36
- UTHR $266.98
- 52 Week High
- JLL $288.50
- UTHR $417.82
- Technical
- Relative Strength Index (RSI)
- JLL 61.43
- UTHR 51.32
- Support Level
- JLL $251.91
- UTHR $286.68
- Resistance Level
- JLL $261.32
- UTHR $301.75
- Average True Range (ATR)
- JLL 5.84
- UTHR 6.73
- MACD
- JLL 0.03
- UTHR 1.81
- Stochastic Oscillator
- JLL 79.50
- UTHR 77.16
About JLL Jones Lang LaSalle Incorporated
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $74 billion for clients across diverse public and private real estate strategies.
About UTHR United Therapeutics Corporation
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.